REGN5837

· Regeneron Pharmaceuticals

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for REGN5837, covering 2026-03-30 to 2026-03-30. Get the full timeline:

Most recent: Clinical Trial Update: A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas [Phase 1]

See pricing